The European Commission granted final approval to Mylan NV's merger with Pfizer Inc. generics and off-patent drugs unit Upjohn.

Viatris — the combination of the Upjohn division, which includes New York-based Pfizer's off-patent drugs like Viagra and Lipitor, and Mylan — had received conditional approval in April, subject to subject to the divestiture of certain products of Mylan in Europe.

The European regulator approved the proposed divestitures, which are substantially in line with Mylan's previously stated expectations, the companies said in a Sept. 15 press release.

The business combination also received approvals from the Australian Competition and Consumer Commission and the New Zealand Commerce Commission.

The deal is on track to close in the fourth quarter, pending approval in the U.S., said Robert Coury, future Viatris executive chairman and current Mylan executive chairman.